J&J's TREMFYA Shows First MRI-Confirmed Improvement in Axial…

Event summary

J&J's TREMFYA met primary and secondary endpoints in the Phase 4 STAR study, showing improvement in spinal pain and stiffness in axial psoriatic arthritis (PsA) patients.
The study is the first to use MRI assessments to confirm axial inflammation reduction in PsA.
STAR enrolled 411 biologic-naïve adults with active PsA and axial involvement worldwide.
No new safety signals were identified, with the safety profile consistent with TREMFYA's established profile in PsA.

The big picture

J&J's TREMFYA is positioning itself as a first-line treatment for axial PsA, an area with significant unmet need. The STAR study's rigorous design and MRI-confirmed outcomes could set a new standard for evaluating axial involvement in PsA, potentially reshaping treatment paradigms. This milestone follows J&J's recent FDA approval for TREMFYA's label expansion to inhibit joint damage progression in PsA, reinforcing its leadership in immunology therapies.

What we're watching

Regulatory Pathway: Whether the MRI-confirmed data will accelerate FDA approvals for TREMFYA in axial PsA.
Market Positioning: How J&J leverages these results to differentiate TREMFYA from competitors in the IL-23 inhibitor space.
Clinical Adoption: The pace at which rheumatologists and dermatologists integrate TREMFYA into treatment protocols for axial PsA.